Add BrightSurf on Google Email

Synthetic tools conduct messages from station to station in DNA

Researchers used deactivated Cas9 proteins to target key segments of the human genome and synthetically trigger gene transcription. The study revealed that enhancers can send messages in both directions, but with a predominant regulatory mode where an enhancer tracks toward corresponding promoters.

SourceRice University·JournalNucleic Acids Research·TypeExperimental study·DateJul 18, 2022

A new treatment approach for cystic fibrosis

A new treatment approach using antisense oligonucleotides (ASOs) may help reduce cystic fibrosis symptoms and improve quality of life for patients with a specific gene mutation. The ASO strategy tricks cells into making an imperfect but functional version of the CFTR protein, which is better than having none at all.

SourceCold Spring Harbor Laboratory·JournalNature Communications·DateJul 14, 2022

Wireless activation of targeted brain circuits in less than one second

Researchers from Rice University, Duke University, Brown University and Baylor College of Medicine developed a magnetic technology to wirelessly control neural circuits in fruit flies. They used genetic engineering to express heat-sensitive ion channels in neurons that control the behavior, and iron nanoparticles to activate the channels.

SourceRice University·JournalNature Materials·TypeExperimental study·DateJul 14, 2022

Genetic discovery to improve lung cancer treatment

Researchers at Edith Cowan University have found a genetic link between human leukocyte antigens and immunotherapy side effects in non-small cell lung cancer patients. The discovery enables doctors to tailor treatment to individual patients, reducing the risk of toxicities and improving overall outcomes.

SourceEdith Cowan University·JournalEuropean Journal of Cancer·TypeRandomized controlled/clinical trial·DateJul 13, 2022

Cleveland Clinic research suggests tumors with specific genetic mutations are sensitive to immunotherapy

Researchers at Cleveland Clinic discovered that pathogenic POLE/POLD1 genetic mutations in tumors lead to a high level of immune cell infiltration and improved response to immune checkpoint blockade therapy. The study's findings contribute to the growing list of discoveries that prove certain classes of drugs are more effective based o...

SourceCleveland Clinic·JournalNature Genetics·DateJul 12, 2022

The cost of living with sickle cell disease

A new study reveals that individuals with sickle cell disease spend approximately $1.7 million on lifetime medical expenses, highlighting the significant economic burden of living with this disease. The study found that out-of-pocket costs for those with private insurance plans can be as high as 5-10% of their annual income.

SourceAmerican Society of Hematology·JournalBlood Advances·DateMay 16, 2022

Patient-derived micro-organospheres enable cutting-edge precision oncology

Researchers developed a droplet-based microfluidic technology to produce micro-organospheres from cancer patient biopsies within an hour. These miniature tumors retain the original microenvironment and can be used for testing many drug conditions, showing almost perfect correlation with actual clinical treatment outcomes.

SourceTerasaki Institute for Biomedical Innovation·JournalCell Stem Cell·TypeExperimental study·DateMay 5, 2022

New tool to create hearing cells lost in aging

Scientists have discovered a master gene that programs ear hair cells into either outer or inner ones, enabling the development of these cells to restore hearing. This breakthrough could provide a previously unavailable tool to create specific hair cells and improve treatments for age-related hearing loss.

SourceNorthwestern University·JournalNature·DateMay 4, 2022

New UCI-led study lays foundation for establishing base editing as a one-time, durable treatment for inherited retinal degeneration

A new UCI-led study indicates base editing has tremendous potential to treat inherited retinal degeneration, particularly in Leber congenital amaurosis (LCA) patients. The treatment rescued cone photoreceptors on a long-term basis, suggesting a one-time, durable treatment for LCA patients.

SourceUniversity of California - Irvine·JournalNature Communications·DateApr 5, 2022

Researchers expand target range of CRISPR/Cas Systems

Scientists have developed a new approach to expand the target range of CRISPR/Cas systems, allowing for slight variations in target DNA while maintaining local specificity. This technology could help realize the potential of CRISPR/Cas-based gene therapy and pathogen diagnosis, particularly for diagnostics.

SourceUniversity of Toronto·JournalNature Communications·TypeExperimental study·DateMar 29, 2022

Correcting night blindness in dogs

Researchers have developed a gene therapy that restores night vision in dogs with congenital stationary night blindness (CSNB), a condition affecting the ON bipolar cells. The treatment enables dogs to navigate mazes in dim light and has a lasting therapeutic effect, paving the way for potential human treatments.

SourceUniversity of Pennsylvania·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateMar 22, 2022